Prevalence of Rubella Antibodies among Fertile Women in the West of Romania, 18 Years after the Implementation of Immunization
Abstract
:1. Introduction
2. Materials and Methods
2.1. Participants and Study Design
2.2. Variables and Methods
2.3. Data Analysis Procedure
3. Results
3.1. Demographic Characteristics of Study Participants
3.2. Seroprevalence of Rubella among Fertile Women
3.3. Seroprevalence of Rubella among Fertile Women According to Demographic Parameters
4. Discussion
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Conflicts of Interest
References
- Lambert, N.; Strebel, P.; Orenstein, W.; Icenogle, J.; Poland, G.A. Rubella. Lancet 2015, 385, 2297–2307. [Google Scholar] [CrossRef] [Green Version]
- Bouthry, E.; Picone, O.; Hamdi, G.; Grangeot-Keros, L.; Ayoubi, J.-M.; Vauloup-Fellous, C. Rubella and pregnancy: Diagnosis, management and outcomes. Prenat. Diagn. 2014, 34, 1246–1253. [Google Scholar] [CrossRef] [PubMed]
- Leung, A.K.C.; Hon, K.L.; Leong, K.F. Rubella (German measles) revisited. Hong Kong Med. J. 2019, 25, 134–141. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Dontigny, L.; Arsenault, M.Y.; Martel, M.J. No. 203—Rubella in Pregnancy. J. Obstet. Gynaecol. Can. 2018, 40, e615–e621. [Google Scholar] [CrossRef] [PubMed]
- Kaushik, A.; Verma, S.; Kumar, P. Congenital rubella syndrome: A brief review of public health perspectives. Indian J. Public Health 2018, 62, 52–54. [Google Scholar] [PubMed]
- Rubella. Available online: https://www.who.int/en/news-room/fact-sheets/detail/rubella (accessed on 26 June 2020).
- Pandolfi, E.; Gesualdo, F.; Rizzo, C.; Bella, A.; Agricola, E.; Mastroiacovo, P.; Tozzi, A. Global seroprevalence of rubella among pregnant and childbearing age women: A meta-analysis. Eur. J. Public Health 2017, 2, 530–537. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- WHO. Weekly Epidemiological Record. Available online: https://www.who.int/wer/2011/wer8647.pdf?ua=1 (accessed on 6 November 2020).
- Demicheli, V.; Rivetti, A.; Debalini, M.G.; Di Pietrantonj, C. Vaccines for measles, mumps and rubella in children. Cochrane Database Syst. Rev. 2012, 2012, CD004407. [Google Scholar] [CrossRef] [PubMed]
- 2020 Recommended Vaccinations for Infants and Children (Birth through 6 Years) Parent-Friendly Version. Available online: https://www.cdc.gov/vaccines/schedules/easy-to-read/child-easyread.html (accessed on 10 January 2021).
- Gorun, F.; Motoi, S.; Malita, D.; Navolan, D.B.; Nemescu, D.; Olariu, T.R.; Craina, M.; Vilibic-Cavlek, T.; Ciohat, I.; Boda, D.; et al. Cytomegalovirus seroprevalence in pregnant women in the western region of Romania: A large-scale study. Exp. Ther. Med. 2020, 20, 2439–2443. [Google Scholar] [CrossRef] [PubMed]
- Motoi, S.; Navolan, D.B.; Malita, D.; Ciohat, I.; Nemescu, D.; Manciuc, C.; Gorun, F.; Vilibic-Cavlek, T.; Boda, D.; Craina, M.; et al. A decreasing trend in Toxoplasma gondii seroprevalence among pregnant women in Romania—Results of a large scale study. Exp. Ther. Med. 2020, 20, 3536–3540. [Google Scholar] [CrossRef] [PubMed]
- Warnecke, J.M.; Pollmann, M.; Borchardt-Lohölter, V.; Moreira-Soto, A.; Kaya, S.; Sener, A.G.; Gómez-Guzmán, E.; Figueroa-Hernández, L.; Li, W.; Li, F.; et al. Seroprevalences of antibodies against ToRCH infectious pathogens in women of childbearing age residing in Brazil, Mexico, Germany, Poland, Turkey and China. Epidemiol. Infect. 2020, 148, e271. [Google Scholar] [CrossRef] [PubMed]
- Lo Giudice, D.; Cannavò, G.; Capua, A.; Grillo, O.C.; La Fauci, V.; Puliafito, A.; Sindoni, D.; Squeri, R.; Calimeri, S. Eliminating congenital rubella: A seroepidemiological study on women of childbearing age and MMR vaccine coverage in newborns. J. Prev. Med. Hyg. 2009, 50, 236–240. [Google Scholar] [PubMed]
- Vilibic-Cavlek, T.; Ljubin-Sternak, S.; Ban, M.; Kolaric, B.; Sviben, M.; Mlinaric-Galinovic, G. Seroprevalence of TORCH infections in women of childbearing age in Croatia. J. Matern. Fetal Neonatal Med. 2011, 24, 280–283. [Google Scholar] [CrossRef] [PubMed]
- Nardone, A.; Tischer, A.; Andrews, N.; Backhouse, J.; Theeten, H.; Gatcheva, N.; Zarvou, M.; Kriz, B.; Pebody, R.G.; Bartha, K.; et al. Comparison of rubella seroepidemiology in 17 countries: Progress towards international disease control targets. Bull. World Health Organ. 2008, 86, 118–125. [Google Scholar] [CrossRef] [PubMed]
- WHO. Measles and Rubella Global Strategic Plan 2012–2020 Midterm Review. Available online: https://www.who.int/immunization/sage/meetings/2016/october/1_MTR_Report_Final_Color_Sept_20_v2.pdf (accessed on 23 February 2020).
- European Centre for Disease Prevention and Control. Monthly Measles and Rubella Monitoring Report. Available online: https://www.ecdc.europa.eu/sites/portal/files/documents/measles-and-rubella-monitoring-report-Sep-2018.pdf (accessed on 6 November 2020).
- European Centre for Disease Prevention and Control. Measles and Rubella Monitoring, July 2016. Available online: https://www.ecdc.europa.eu/sites/portal/files/media/en/publications/Publications/measles-rubella-monitoring-july-2016.pdf (accessed on 6 November 2020).
- WHO Regional Office for Europe. Seventh Meeting of the European Regional Verification Commission for Measles and Rubella Elimination (RVC). Available online: https://www.euro.who.int/en/health-topics/communicable-diseases/measles-and-rubella/publications/2018/7th-meeting-of-the-european-regional-verification-commission-for-measles-and-rubella-elimination-rvc.-report (accessed on 6 November 2020).
- European Centre for Disease Prevention and Control. Monthly Measles and Rubella Monitoring Report April 2020. Available online: https://www.ecdc.europa.eu/en/publications-data/monthly-measles-and-rubella-monitoring-report-april-2020 (accessed on 6 November 2020).
- National Institute of Public Health Romania. National Center for Surveillance and Control of Communicable Diseases. Analysis of the Evolution of Communicable Diseases under Surveillance, Report for 2010. Available online: http://www.cnscbt.ro/index.php/rapoarte-anuale/544-analiza-evolutiei-bolilor-transmisibile-aflate-in-supraveghere-raport-pentru-anul-2010 (accessed on 3 April 2020).
- National Institute of Public Health Romania. National Center for Surveillance and Control of Communicable Diseases. Analysis of the Evolution of Communicable Diseases under Surveillance, Report for 2018. Available online: http://www.cnscbt.ro/index.php/rapoarte-anuale/1302-analiza-bolilor-transmisibile-aflate-in-supraveghere-raport-pentru-anul-2018 (accessed on 3 April 2020).
- WHO. Measles and Rubella Elimination Country Profile Romania. Available online: https://www.euro.who.int/__data/assets/pdf_file/0015/401217/ROU.pdf (accessed on 3 April 2020).
- National Institute of Public Health Romania. National Center for Surveillance and Control of Communicable Diseases. The Evolution of the Rubella Epidemic, September 2011–December 2012. Available online: https://www.cnscbt.ro/index.php/analiza-date-supraveghere/rubeola/154-evolutia-epidemiei-de-rubeola/file (accessed on 3 April 2020).
- Tabacchi, G.; Costantino, C.; Napoli, G.; Marchese, V.; Cracchiolo, M.; Casuccio, A.; Vitale, F.; The Esculapio Working Group. Determinants of European parents’ decision on the vaccination of their children against measles, mumps and rubella: A systematic review and meta-analysis. Hum. Vaccines Immunother. 2016, 12, 1909–1923. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- DeStefano, F.; Shimabukuro, T.T. The MMR Vaccine and Autism. Annu. Rev. Virol. 2019, 6, 585–600. [Google Scholar] [CrossRef] [PubMed]
- Spencer, J.P.; Trondsen Pawlowski, R.H.; Thomas, S. Vaccine Adverse Events: Separating Myth from Reality. Am. Fam. Physician. 2017, 95, 786–794. [Google Scholar] [PubMed]
- Godlee, F.; Smith, J.; Marcovitch, H. Wakefield’s article linking MMR vaccine and autism was fraudulent. BMJ 2011, 342, c7452. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- MacDonald, N.E.; SAGE Working Group on Vaccine Hesitancy. Vaccine hesitancy: Definition, scope and determinants. Vaccine 2015, 33, 4161–4164. [Google Scholar] [CrossRef] [PubMed]
- The Lancet Child Adolescent Health. Vaccine hesitancy: A generation at risk. Lancet Child Adolesc. Health 2019, 3, 281. [Google Scholar]
- The Sage Working Group. Report of the Sage Working Group on Vaccine Hesitancy. Available online: https://www.who.int/immunization/sage/meetings/2014/october/1_Report_WORKING_GROUP_vaccine_hesitancy_final.pdf (accessed on 3 April 2020).
- Rubella. Available online: https://www.historyofvaccines.org/content/articles/rubella (accessed on 29 October 2020).
- Morbidity and Mortality Weekly Report (MMWR). Available online: https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6204a1.htm (accessed on 6 December 2020).
- Kirby, T. Rubella is eliminated from the Americas. Lancet Infect. Dis. 2015, 15, 768–769. [Google Scholar] [CrossRef]
Group 1 (Tested 2008–2010) | ||||||||
<1989 | 1989–1994 | 1995–1996 | >1997 | |||||
Overall % (95% CI) | 1336/1422 94.0% (95.1–92.6) | Ref. | 30/30 100% (86.6–100) | OR = 3.94 (p = 0.25) | ||||
Urban %(95% CI) | 977/1038 94.1% (92.5–95.4) | Ref. | 8/8 100% (67.6–100) | NA | - | - | ||
Rural % (95% CI) | 359/384 93.5% (90.6–95.6) | Ref. | 22/22 100% (85.1–100) | OR = 0.0 (p = 0.38) | - | - | ||
OR (p value) 1 | 0.84 (0.52) | - | - | - | - | - | ||
Group 2 (Tested 2015–2018) | ||||||||
<1989 | 1989–1994 | 1995–1996 | >1997 | |||||
Overall % (95% CI) | 2900/3218 90.1% (89.0–91.1) | Ref. | 1701/1776 95.8% (94.7–96.6) | OR = 2.48 (p < 0.0001) | 211/247 85.4% (80.5–89.3) | OR = 0.64 (p = 0.02) | 182/221 82.4% (76.8–86.8) | OR = 0.51 (p = 0.006) |
Urban % (95% CI) | 2341/2591 90.4% (89.2–91.4) | Ref. | 752/776 96.9% (95.4–97.9) | OR = 3.3 (p < 0.0001) | 87/96 90.6% (83.1–95.0) | OR = 1.03 (p > 0.99) | 67/80 83.8% (74.2–90.3) | OR = 0.55 (p = 0.05) |
Rural % (95% CI) | 957/1045 91.6% (89.7–93.1) | Ref. | 551/582 94.7% (92.5–96.2) | OR = 1.6 (p = 0.02) | 124/151 82.1% (75.2–87.4) | OR = 0.42 (p = 0.0006) | 115/141 81.6% (74.4–87.1) | OR = 0.40 (p = 0.0006) |
OR (p value) 1 | 1.16 (0.25) | - | 0.56 (0.05) | - | 0.47 (0.06) | - | 0.85 (0.71) |
Age (Years) | Group 1 (Tested 2008–2010) | Group 2 (Tested 2015–2018) | ||
---|---|---|---|---|
No. (Positive/Total) % (95% CI) | OR (p Value) | No. (Positive/Total) % (95% CI) | OR (p Value) | |
<25 | 395/417 94.7 (92.1–96.5) | Ref. | 1190/1303 91.3 (89.7–92.7) | Ref. |
26–34 | 881/941 93.6 (91.9–95.0) | 0.81 (0.46) | 2918/3180 91.8 (90.8–92.7) | 1.05 (0.63) |
>35 | 90/94 95.7 (89.6–98.3) | 1.25 (>0.99) | 886/979 90.5 (88.5–92.2) | 0.90 (0.50) |
Publisher’s Note: MDPI stays neutral with regard to jurisdictional claims in published maps and institutional affiliations. |
© 2021 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Gorun, F.; Malita, D.; Ciohat, I.; Vilibic-Cavlek, T.; Feier, H.; Tabain, I.; Craina, M.; Cretu, O.; Navolan, D. Prevalence of Rubella Antibodies among Fertile Women in the West of Romania, 18 Years after the Implementation of Immunization. Vaccines 2021, 9, 104. https://doi.org/10.3390/vaccines9020104
Gorun F, Malita D, Ciohat I, Vilibic-Cavlek T, Feier H, Tabain I, Craina M, Cretu O, Navolan D. Prevalence of Rubella Antibodies among Fertile Women in the West of Romania, 18 Years after the Implementation of Immunization. Vaccines. 2021; 9(2):104. https://doi.org/10.3390/vaccines9020104
Chicago/Turabian StyleGorun, Florin, Daniel Malita, Ioana Ciohat, Tatjana Vilibic-Cavlek, Horea Feier, Irena Tabain, Marius Craina, Octavian Cretu, and Dan Navolan. 2021. "Prevalence of Rubella Antibodies among Fertile Women in the West of Romania, 18 Years after the Implementation of Immunization" Vaccines 9, no. 2: 104. https://doi.org/10.3390/vaccines9020104